Trial Profile
Effectiveness and safety of tafluprost 0.0015% mono-therapy in Chinese patients with primary open-angle glaucoma and ocular hypertension
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 21 Jun 2019
Price :
$35
*
At a glance
- Drugs Tafluprost (Primary)
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Therapeutic Use
- Sponsors Santen Pharmaceutical
- 18 Jul 2017 New trial record